Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01580241 · ClinicalTrials.gov registry record
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
A clinical trial, sponsored by University of Oklahoma.
- Active
- Registry status
- 60
- Enrollment target
NCT01580241 is a clinical trial that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 60 participants.
The verdict
NCT01580241 is active but no longer recruiting, sponsored by University of Oklahoma.
- ACTIVE NOT RECRUITING
- Registry status
- 60 participants
- Enrollment target
Study Summary
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-10 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01580241
The ClinicalTrials.gov registry entry for NCT01580241 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01580241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01580241 about?
NCT01580241 is a clinical study titled "Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer". The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
What is the current status of trial NCT01580241?
This trial is currently active not recruiting. The enrollment target is 60 participants. The study started on 2010-10. Estimated completion is 2027-12.
Who is sponsoring clinical trial NCT01580241?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.